SecBot SecBot

INVA drug pipeline

Innoviva, Inc. · 5 rated drugs
$19.03
+0.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.4%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
5
5 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available (FDA approved December 2017).

GIAPREZA angiotensin ii Updated Nov 6

What to watch

GIAPREZA has no upcoming FDA decision or pivotal readout; the next catalyst for Innoviva is the Q4 2026 earnings report (likely February 2027), where GIAPREZA's continued sales growth trajectory will be the key metric to watch. The drug's $23.1M quarterly run rate is on pace to help Innoviva hit its at-least-$150M full-year IST product sales guidance.

Bull case
  • GIAPREZA is the first and only FDA-approved synthetic angiotensin II vasopressor, giving it a unique mechanism in the septic-shock treatment algorithm as an add-on when traditional vasopressors like norepinephrine fail.
  • U.S. net product sales of GIAPREZA reached $23.1 million in Q3 2026, contributing to 45% year-over-year growth in Innoviva's IST platform, which is on track to hit at least $150 million in full-year 2026 sales.
  • Innoviva acquired the drug for just $149M in 2022 and has successfully grown sales; at the current quarterly run rate, GIAPREZA alone is on pace for ~$85-90M in annualized U.S. sales, representing a strong return on the acquisition cost.
Bear case
  • GIAPREZA competes in the ICU vasopressor market against cheap, established generics like norepinephrine and vasopressin, limiting its pricing power and adoption to refractory cases only.
  • The drug was originally a laggard under La Jolla (prompting the $149M fire sale to Innoviva in 2022), and while sales have grown under Innoviva, the addressable market is narrow (refractory septic shock patients).
  • Patent protection is estimated to expire around 2031-2037, and with 11 Orange Book patents, generic entry remains a long-term overhang.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US since May 2023.

XACDURO sulbactam/durlobactam Updated Nov 6

What to watch

XACDURO is already approved and commercializing, so there is no single binary catalyst ahead. Watch quarterly IST product sales growth (Innoviva guided to at least $150M in total IST US net product sales for 2026) and any updates on the Dr. Reddy's international licensing deal. The stock trades near its 52-week low with a mean analyst price target of $35, implying significant upside if the commercial ramp continues, but the Q3 net loss of $73.9M from investment fair-value changes introduces headline risk.

Bull case
  • XACDURO is the first and only FDA-approved pathogen-targeted antibiotic for Acinetobacter, a serious multidrug-resistant hospital infection with high unmet need.
  • Q3 2026 XACDURO US net sales reached $16.1M, contributing to IST's 45% year-over-year growth, with full-year 2026 IST guidance of at least $150M in US net product sales.
  • The June 2026 Dr. Reddy's licensing deal extends XACDURO into South/Central America, the Caribbean, Russia and other international markets with upfront and milestone payments.
Bear case
  • XACDURO addresses a niche, multidrug-resistant Acinetobacter pneumonia market valued at roughly $350-530M globally, capping peak sales potential.
  • Innoviva swung to a $73.9M net loss in Q3 2026, driven by unfavorable changes in investment fair values, adding headline risk.
  • Several large institutional holders trimmed or exited INVA in Q2/Q3 2026, including Arrowstreet Capital (near-exit, -82%), Man Group (exit, -100%), and JPMorgan (trim, -59%).
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US since May 2025.

ZEVTERA ceftobiprole medocaril Updated Nov 6

What to watch

ZEVTERA is already approved and commercially available, so the next catalysts are quarterly sales figures and formulary adoption updates. Watch Innoviva's Q4 2026 earnings (expected early February 2027) for ZEVTERA's contribution to the IST product sales trajectory and whether the company raises its 2027 guidance. The stock trades near its 52-week low (~$19) with a mean analyst price target of $35, implying the market may be discounting the commercial ramp.

Bull case
  • ZEVTERA is the first and only FDA-approved cephalosporin for Staphylococcus aureus bacteremia (SAB) including MRSA-caused right-sided endocarditis, addressing a significant unmet medical need with no direct cephalosporin competitor.
  • Innoviva's IST segment delivered $43.3M in US net product sales in Q3 2026 (45% YoY growth), and the company is on track for at least $150M in full-year 2026 product sales, with ZEVTERA as a key growth driver.
  • The drug has 10 years of US market exclusivity and was designated a finalist for the 2026 Prix Galien USA Best Pharmaceutical Product Award, reflecting clinical differentiation.
Bear case
  • ZEVTERA faces entrenched competition from established MRSA antibiotics like daptomycin (Cubicin) and vancomycin, which have decades of clinical experience and formulary positioning.
  • Innoviva's Q3 2026 net loss of $73.9M (driven by $139.5M in unfavorable investment fair-value changes) and total revenue decline of 1.6% YoY raise questions about the company's overall financial trajectory despite product sales growth.
  • Several large institutional holders (Arrowstreet Capital, Man Group, JPMorgan) significantly trimmed or exited INVA positions in Q2 2026, signaling mixed institutional conviction.
● neutral
Impact
PhaseApproved (FDA since 2018)
Time to marketAlready on the market (approved in the US since 2018, in China since 2023).

XERAVA eravacycline Updated Nov 6

What to watch

XERAVA has no scheduled binary catalyst to watch. The next relevant event for Innoviva overall is the Q3 2026 earnings call on November 11, 2026, which will report aggregate IST product sales. Investors interested in XERAVA-specific signals should track pediatric trial results (NCT06794541) and any updates to IDSA/SIS treatment guidelines, but neither provides a hard, dated binary for the stock.

Bull case
  • XERAVA addresses a clear unmet need: multi-drug resistant Gram-negative infections in hospitalized patients, a growing public health threat. It was named in the 2024 Surgical Infection Society guidelines as a recommended agent for empiric therapy in cIAI, which should support adoption. The drug benefits from QIDP (Qualified Infectious Disease Product) exclusivity extending to August 2028 under the GAIN Act, providing some regulatory protection. Innoviva's IST commercial platform continues to grow overall product sales 45% year-over-year in Q3 2026, suggesting improving commercial execution.
Bear case
  • XERAVA is a very small contributor to Innoviva's business: only $3.4 million in Q3 2026 U.S. net product sales, or about 3.2% of the company's total quarterly revenue of $106.1 million. It competes against many well-established, cheaper generic antibiotics (meropenem, imipenem, piperacillin-tazobactam) and newer branded products like AbbVie's AVYCAZ. Hospital antibiotic markets are notoriously difficult to grow given pressure to use lowest-cost alternatives. Oral formulation was discontinued, limiting the drug to IV-only hospital use. The NCE (New Chemical Entity) exclusivity expired in August 2023, and the remaining patent/regulatory protection is finite.
● neutral
Impact
PhaseFiled/PDUFA (NDA submitted, Priority Review granted, PDUFA date December 15, 2025 passed)
Time to marketUnknown — the PDUFA date of December 15, 2025 has passed with no recorded approval, suggesting the drug may have received a Complete Response Letter (CRL) or rejection. A resubmission timeline, if any, is not available in the data.

zoliflodacin Updated Oct 24

What to watch

The PDUFA catalyst for zoliflodacin (December 15, 2025) has already passed with what appears to have been a negative outcome (stock dropped ~3.4% on the day and continued declining). There is no upcoming hard binary catalyst for this drug in the next 12 months. For INVA investors, zoliflodacin is now a known-quantity overhang; the stock's thesis rests more on the core royalty portfolio and other pipeline assets.

Bull case
  • Zoliflodacin is a novel, first-in-class oral antibiotic for gonorrhea (a bacterial topoisomerase inhibitor) that addresses growing antibiotic resistance, a major public health need.
  • The NDA was granted Priority Review by the FDA, indicating the agency viewed the drug as a significant therapeutic advance.
  • Analyst consensus on INVA is strongly bullish: 9 Buy/Strong Buy vs 2 Hold/Sell, with a mean price target of $35 (67.4% implied upside from ~$20.91).
Bear case
  • The PDUFA date of December 15, 2025 has passed with no recorded FDA approval, the stock dropped -3.44% on the decision date and continued falling to ~$19.30 in late December, strongly suggesting a Complete Response Letter (CRL) or rejection.
  • With no upcoming binary catalyst for this drug, there is no near-term positive event to re-rate the stock on this asset.
  • The drug treats uncomplicated gonorrhea, a large but generic-heavy market where pricing and adoption of a new branded antibiotic face headwinds.

Other drugs in filings and trials

no drug report yet
  • NUZOLVENCE Last: Approval · Dec 10, 2025

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Dec 15, 2025zoliflodacinPDUFA decision−3.4%−3.1%
Dec 15, 2025zoliflodacinPriority review−3.4%−3.1%
Dec 10, 2025NUZOLVENCEApproval−0.4%−3.2%
Dec 1, 2025NUZOLVENCEApproval−3.5%−3.4%
Jun 1, 2025zoliflodacinNDA filed+2.9%+10.3%